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                                     INTRODUCTION
HISTORICAL BACKGROUND
Gout is  an inflammatory arthritis  mediated by crystallization of uric  acid within the 
joints.  Gout  has  been  called  the  king  of  kings  and  the  disease  of  kings.  The  term  gout 
introduced in the thirteenth century is derived from the Latin word “Gutta”a drop and reflects 
the early belief that a poison falling drop by drop into the joint was responsible for the disease. 
Hippocrates described gout as podagra, chiegra, gonagra depending on the site of involvement, 
the  foot  the  wrist  or  the  knee.  Tophi  were  first  described  by  Galen.  Thomas  Sydenham’s 
unsurpassed description marked the modern clinical history of gout. Wollartanin (1797) and 
Pearson  (1798)  demonstrated  urate  in  the  tophi  of  patients  with  gout.  Leeuwenhock  the 
inventor of the microscope first described these crystals in 1679. In 1848 Garrod demonstrated 
an increased amount of uric acid in the blood of gouty patients.
Today gout is used to represent a heterogenous group of diseases found exclusively in 
human species that includes:-
 Elevated serum urate concentration (hyperuricemia)
 Recurrent attacks of acute arthritis in which monosodium urate monohydrate crystals 
are demonstrable in the synovial fluid leukocytes.
 Aggregates of monosodium urate monohydrate crystals (tophi) deposited chiefly in 
and around joints which sometimes leads to deformity and crippling.  
 Renal disease involving glomerular, tubular and interstitial tissues and blood vessels, 
uric acid nephrolithiasis   
Hyperuricemia is a term representing an elevated level of urate in blood..This occurs in 
an  absolute  sense  when  the  serum  urate  concentration  exceeds  the  limit  of  solubility  of 
monosodium urate in the serum, which is about 7mg/dl at 37.c.The serum urate concentration is 
elevated in a relative sense when it exceeds the upper limit of an arbitrary normal range which 
is  usually defined as mean serum urate value plus two standard deviations in sex and age 
matched healthy populations. In most epidemiologic studies the upper limit has been rounded 
off at 7mg/dl in men and 6mg/dl in women. 
EPIDEMIOLOGY
The prevalence of gout is increasing globally. Hyperuricemia is fairly common with a 
prevalence  ranging  from  2.3  to  41.4  percent  in  various  populations.  .Serum  urate 
concentrations vary with age and sex .Children has a concentration in the range of 3-4mg/dl 
because of high renal uric acid clearance. At puberty, serum urate concentrations increase by 1 
to 2 mg/dl in males, with these higher levels generally sustained throughout life. The Incidence 
of gout increases with the age in both sexes. Serum urate levels also tend increase with aging in 
women, but the trend is less clear in men. Age associated risk factors for hyperuricemia and 
gout might explain   to a certain extent the cause for increasing incidence of gout with older 
age.   Although the  prevalence and incidence  of  gout  are  substantially  higher  in  men than 
women before menopause, the disease burden in women tends to approach that of men after 
menopause. The mechanism of lower serum urate levels in women is a consequence of sex 
hormones and is related to a higher fractional excretion of urate secondary to a lower tubular 
urate post secretory reabsorption.
A variety of factors appear to be associated with higher serum uric acid concentrations. 
In adults,  serum urate levels correlate strongly with the serum creatinine and urea nitrogen 
levels, bodyweight, height, age, blood pressure and alcohol intake. Body weight has proved to 
be one of the most important predictors of hyperuricemia in people of widely differing races 
and cultures with rare exceptions.
The incidence of gout varies in populations, with an overall prevalence of less than 1 to 
15.3 percent and appears to be increasing. The prevalence seems to be increasing substantially 
with age and increasing serum urate concentration. The annual incidence of gout is 4.9 percent 
for  urate  levels  greater  than  9mg/dl,  0.5  percent  for  values  between  7  and  8.9mg/dl,  and 
0.1percent  for  values  less  than  7mg/dl.For  serum  urate  values  greater  than  9mg/dl,  the 
cumulative incidence of gout reaches 22 percent after 5 years.
CLINICAL FEATURES
 In the complete development of its natural  history gout passes through four stages, 
asymptomatic hyperuricemia, acute gouty arthritis, intercritical gout and chronic tophaceous 
gout.  The  usual  presentation  is  acute  attacks  of  exquisitely  painful  arthritis  usually 
monoarticular  during  the  initial  attacks  associated  with  a  few  constitutional  symptoms 
.Subsequently the attacks become  polyarticular and lasting for  a variable but limited time and 
separated  completely  by  asymptomatic  intervals.  Attacks  recur  at  progressively  shorter 
intervals  and  eventually  resolve  incompletely  leaving  in  a  train  of  chronic  arthritis  which 
slowly progresses to a crippling disease on which acute exacerbations are superimposed.
ACUTE GOUTY ARTHRITIS
The peak age of onset of acute gouty arthritis was in the fourth, fifth or sixth decade in 
various studies. Onset before the age of thirty should raise the question of an unusual form of 
gout perhaps related to a specific enzymatic defect causing over production of purines or rarely 
to a unususal form of parenchymal renal disease. In 85 to 90 percent of first attacks a single 
joint is involved. In atleast, half of the initial acute attacks, the first metatarsophalangeal joint is 
the site of the involvement. 
Both the great toes were involved simultaneously in 5 percent of subjects in the first 
attack.  Percentage  of  initial  attacks  of  polyarticular  gout  was  variable.  Ninety  percent  of 
patients with gout experience acute attacks in the great toe at some during the course of their 
disease. Next in frequency are the insteps, ankles, heels, knees, wrists, fingers, and elbows. 
Gout is predominantly a disease of the lower extremity but any joint may be involved. Rare 
sites are shoulders, hips, spine, sacroiliac, sternoclavicular and temporomandibular joints. The 
more distal the site the more typical is the character of the attack. Acute gouty bursitis also 
occurs  and  mainly  involves  the  prepatellar  and  olecranon  bursa.  Urate  deposition  and 
subsequent gout appear to have a predilection for previously damaged joints. Gout occurs in the 
heberdens nodes of older women.
In most patients, the initial attack occurs with an explosive suddenness and commonly 
begins at night after the individual has gone to a good sleep. Within a few hours after onset, the 
affected  joint  becomes  hot,  dusky  red,  swollen  and    extremely  tender.  Occasionally, 
lymphangitis may develop. Systemic signs of inflammation may include leukocytosis, fever, 
and elevation of ESR. The course of untreated acute gout is variable. 
Mild attacks may subside in a few hours or persist for a day or two and never reach the 
intensity described for classic attack. Severe attacks may last for days to weeks. The skin over 
the affected joint may desquamate as the attack subsides. With resolution, the patient becomes 
asymptomatic and enters the intercritical period.
The definitive diagnosis is established by aspiration of the joint and identification of 
intracellular  needle-shaped  crystals  that  have  negative  birefringence  with  compensated 
polarized light  microscopy,  but  criteria  have been proposed for  the  presumptive  diagnosis, 
which are triad of acute monoarticular arthritis,  hyperuricemia,  and a dramatic response to 
colchicines therapy; along with the criteria proposed by American college of Rheumatology.
Intercritical gout
This  is  the  period  between  gouty  attacks.  Some  never  have  a  second  attack.  The 
frequency of gout attacks usually increases with time in untreated patients. Later attacks have a 
less explosive onset, more severe, last longer abate more gradually & usually polyarticular. 
Nevertheless, recovery is complete.
Radiographic changes develop during the intercritical period despite no sign of tophi on 
physical examination. These changes are more likely in those with more severe hyperuricemia 
and more  frequent  acute  attacks.  The  diagnosis  of  gout  in  a  hyperuricemic  patient  with  a 
history of acute attacks of monoarthritis may be difficult or inconclusive during the intercritical 
phase. 
Aspiration of an asymptomatic joint, however can be a useful adjunct in the diagnosis of 
gout  if   urate  crystals  are  demonstable.  Joint  fluids  obtained  from  gouty  patients  during 
intercritical  phase  revealed  monosodium crystals  in  12.5 to  90 percent  of  the  joints.  Such 
crystals  in  asymptomatic  joints  are  often  associated  with  mild  synovial  fluid  leukocytosis, 
which suggests  the  potential  for  contribution to joint  damage even in the interval  between 
attacks.
CHRONIC TOPHACEOUS GOUT
When recurrent acute gout and hyperuricemia go untreated and when there is a failure 
to eradicate causative factors such as alcohol excess, obesity or  diuretic therapy, the condition 
may evolve from a  picture   of  sporadic   acute  mono  and  oligoarthritis  through recurrent 
polyarthritis  to persistent low grade joint inflammation, joint deformity and deposition of urate 
crystals  to form visible tophi. The time from the initial attack to the beginning of chronic 
symptoms or visible tophaceous involvement is highly variable in studies of untreated patients. 
The intervals range from 3 to 42 years with an average of 11.6 years between first attack and 
the  development  of  chronic  arthritis  .Ten  years  after  the  first  attack,  about  half  of  the 
individuals  were  still  free  of  obvious  tophi,  and  most  of  the  remainder  had  only  minimal 
deposits. Thereafter the proportion of those   with non tophaceous involvement slowly declined 
to 28 percent after 20 years. 
Two percent of the patients had severe crippling disease some 20 years after the initial 
attack. The rate of formation of tophaceous deposits correlates with both the degree and the 
duration of hyperuricemia. The principal determinant is the serum urate levels.  The rate of 
tophus formation also increases with the severity of renal disease and the use of diuretics.
Tophaceous  gout   is  the  consequence  of  the  chronic  inability  to  eliminate  urate  as 
rapidly as  it  is  produced .As the  urate  pool  expands,  deposits  of  urate  crystals   appear  in 
cartilage, synovial membranes, tendons, soft tissue and else where. Tophi are rarely present at 
the  time  of  initial  attack  of  primary  gout,  but  have  been  observed  in  gout  secondary  to 
myeloproliferative diseases, in juvenile gout complicating glycogen storage diseases, in Lesch-
Nyhan syndrome, or after renal allograft transplantation in patients treated with cyclosporine. 
Tophaceous  deposits  develop  within  the  same  joints  affected  by  acute  gout  and 
especially the first metatarsophalangeal joint .The relatively mild discomfort of chronic gout 
may be punctuated by episodes of acute arthritis.  About one third of chronic gout patients 
develop visible tophi. The process of tophaceous deposits advances insidiously. No synovial 
joint is immune to this process. Although the joints of the feet are notoriously involved in the 
acute  illness,  it  is  the  hands  where  evidence  of  chronic  gout  is  more  evident.  Eventually, 
extensive  destruction  of  the  joints  and  large  subcutaneous  tophi  may  lead  to  grotesque 
deformities, particularly of the hands and feet and progressive crippling. 
Swelling of the distal and proximal interphalangeal and metacarpophalangeal joints are 
often due to articular and periarticular tophi. Swan neck, Buttonierre and flexion deformities 
may  develop  resembling  rheumatoid  arthritis.  The  diagnosis  is  suggested  by  the  pallor  of 
tophaceous material beneath the skin which is stretched over an involved joint. Toes, ankles, 
elbows  and  wrists  may  be  similarly  affected.  Within  the  joints,  tophi  contribute  to  the 
development of bone erosions especially in the big toe but also elsewhere. Tophi are classically 
found on the pinnae, the elbows, the Achilles tendon as fusiform enlargements but they may be 
distributed more widely, occurring within and around the finger joints, in the finger tip pulp, 
around the knee and within olecranon and prepatellar bursae .Spinal joints do not escape urate 
deposition but acute gouty spondylitis is unusual.  Symptoms related to nerve or spinalcord 
compression by tophi have been observed. Tophi may also occur in myocardium, valves, the 
cardiac conduction system, various parts of the eye and the larynx. Careful inspection of tophi 
may reveal  a  white subcutaneous  granular appearance due to accumulation of monososium 
crystals. Tophi emerge at unexpected sites becoming suddenly visible and discharging uric acid 
crystals as a paste or pus like material especially during hypouricemic treatment                 
hyperuricemia and associated disease
The association of hyperuricemia and gout with other important disorder continues to be 
documented. Studies in rats, has led to reconsideration of a pathogenic role for hyperuricemia 
independent  of  crystal  deposition  in  hypertension,  chronic  kidney  disease  cardiovascular 
disease  (coronary  heart  disease,  stroke  and  peripheral  artery  disease,  and  congestive  heart 
failure), and aberrant metabolic states, such as hypertriglyceridemia, obesity, insulin resistance, 
and metabolic syndrome. Whether or not hyperuricemia (or even “high normal” serum urate 
levels) plays a causal role or simply is a marker arising in the course of each related disorder 
remains unresolved.
Hyperuricemia and hypertension
An association  of  hyperuricemia  and  hypertension  long has  been  recognized  and  is 
supported by the following observations.
 Prevalence  of  hyperuricemia  of  approximately  20%  to  40%  in  untreated  hypertensive 
patients and approximately 50% to 70% in treated or renally impaired hypertensive patients
  Gout prevalence’s of 2% to 12% in hypertensive patients
 25% to 50% hypertension prevalence’s in groups of patients who have documented gout
 Increasing  prevalence  of  hyperuricemia  with  increasing  blood  pressure  in  the  general 
population. 
 Increasing risk of development of hypertension with increasing baseline serum urate levels.
Therefore, the association between hypertension and hyperuricemia may be related to the 
reduction of renal blood flow in hypertension. In addition, uric acid causes smooth muscle 
proliferation in vitro and vascular disease in animal.
Renal disease
Twenty to forty percent of patients with gout have albuminuria, which is usually mild 
and often intermittent. Hyperuricemia alone may be implicated as the cause of renal damage 
only  when the  concentration of  urate  chronically  exceeds  13mg/dl  in  men or  10mg/  dl  in 
women. Prior to the routine treatment of asymptomatic hypertension, renal failure accounted 
for  10  percent  of  the  deaths  in  patients  with  gout.  Today,  it  appears  that  moderate 
hyperuricemia has no direct harmful effect on renal function. Nevertheless, after gouty arthritis, 
renal problems appear to be the most frequent complication of hyperuricemia. These include 
urate nephropathy uric acid   nephropathy, and nephrolithiasis.
The term urate nephropathy is used to represent the deposition of urate crystals in the 
interstitium of the medulla and pyramids with a surrounding giant cell reaction, a distinctive 
histologic finding characteristic of the gouty kidney. Factors such as coexistent hypertension, 
chronic  lead  exposure,  ischemic  heart  disease,  and  primary  preexistent  renal  insufficiency, 
probably play important roles in the pathogenesis of the pathology. Although urate nephropathy 
appears to exist as a distinct entity, it is not believed to be an important contributor to declining 
renal function in most gouty patient.
Uric acid nephropathy is the term used to represent acute renal failure resulting from the 
precipitation of large quantities of uric acid crystals in the collecting ducts and ureters. This 
complication most commonly occurs in patients with leukemia and lymphomas as a result of 
rapid malignant cell turnover, often during chemotherapy.
Nephrolithiasis  occurs in 10 to 25 percent of patients with primary gout,  prevalence 
greater than that in the general population. The likelihood of stones in a given patient with gout 
increases with the serum urate concentration and with amounts of urinary uric acid excretion. It 
exceeds 50 percent with a serum urate value above 13 mg/dl or with urinary uric acid excretion 
rates in excess of 1100 mg every 24 hours Uric acid stones do occur in patient with no history 
of  gouty  arthritis,  and  only  20  percent  of  this  group are  hyperuricemia.  Other  renal  stone 
disease  is  associated  with  hyperuricemia  and gout.  Gouty  subjects  also  have  an  increased 
incidence of stones that contain calcium. 
In addition, about 30 percent of patients with recurrent calcium stone disease have either 
an increased urinary uric acid excretion rate or hyperuricemia. An etiologic link between uric 
acid and recurrent calcium oxalate stones is provided by the report of reduced stone frequency 
in such patients treated with allopurinol. 
Hyperuricemia has been associated with other familial nephropathies, such as medullary 
cystic  disease,  focal  tubulo interstitial  disease,  and polycystic  kidney disease.  In  fact,  gout 
develops in 24 to 36 percent of individuals with polycystic kidney disease. The hyperuricemia 
and gouty arthritis appear to precede the development of renal failure
hyperuricemia and cardiovascular disease
The association of hyperuricemia with the manifestations of atherosclerosis has led to 
speculation that hyperuricemia is a risk factor for coronary artery disease. Hyperuricemia is 
associated with increased cerebrovascular disease, cardiovascular disease, and cardiovascular 
mortality. Hyperuricemia is an independent risk factor for coronary artery disease. It  seems 
likely  that  in  patient  with  hyperuricemia,  clinical  correlates  such  as  hypertension,  insulin 
resistance,  diabetes  mellitus,  hyperlipidemia,  and  obesity  contribute  meaningfully  to  the 
observed association between elevated serum urate concentrations and atherosclerosis. Whether 
urate levels simply help to identify these patients or play a primary role in the pathogenesis is 
unclear.
Hyperuricemia and metabolic syndrome 
The  term  syndrome  X  has  been  applied  to  a  cluster  of  abnormalities,  including 
resistance  to  insulin-stimulated  glucose  uptake,  hyper  insulinemia,  hypertension,  and 
dyslipoproteinemia,  that  are  characterized by high levels  of  plasma triglycerides  and high-
density  lipoprotein  cholesterol.  Hyperuricemia closely correlates  with the  degree  of  insulin 
resistance and, therefore, is a likely feature of syndrome X. Syndrome X has been associated 
with  coronary  artery  disease,  and  explains  the  previously  recognized  association  between 
coronary artery disease and hyperuricemia.
BMI and waist-to-hip ratio were strongly associated with the risk for incident gout after 
adjusting for various confounders including dietary factor.
Adiposity
Adiposity has been noted to be associated with serum uric acid levels and proposed to 
increase the risk for gout. Factors not related to uric acid, such as chronic joint trauma resulting 
form excess weight,  are proposed as an additional  explanation for  the association between 
obesity and gout.
hyperuricemia &hypothyroidism
There appears to be a significant increase prevalence of hypothyroidism among both 
female patient (25 percent) and male patients with gouty arthritis, in contrast to the rates in 
control  subject  (10 percent  and 2 percent,  respectively).  Hyperuricemia  may also  be  more 
prevalent in patients with hypothyroidism; Thyroid replacement therapy is associated with a 
decrease in serum urate concentration cause by an increased uric acid diuresis, a change not 
explained solely by a change in Creatinine clearance. Although the cause of hyperuricemia and 
gout  inpatients  with  hypothyroidism is  unknown,  it  is  speculated  that  urate  metabolism is 
mediated by thyroid stimulating hormone receptors  in extra  thyroidal  tissues,  including the 
kidney, and that these modulate urate homeostasis.
Other Connective tissue diseases 
Gout  is  rarely  seen  in  patients  with  Rheumatoid  Arthritis,  Systemic  Lupus 
Erythematosus,  or ankylosing spondylitis (AS). The basis for the decreased concurrence of 
these disorders is unclear, although the long-term use of non steroidal anti inflammatory drugs 
(NSAIDs) may mask the clinical features of gout in some of these patients.
Alcohol
Alcohol  consumption  has  long  been  associated  with  hyperuricemia  and  gout.  In 
susceptible persons, alcohol use can lead to the precipitation of acute gouty arthritis with a 
prevalence of hyperuricemia of 8.42 percent. Both a decrease in the renal excretion of uric acid 
and an increase in uric acid production seem to be important factors in this association. Ethanol 
increases uric acid production by accelerating the turnover of adenosine triphosphate (ATP). 
Among  alcoholic  beverages,  beer  may  have  more  potent  effects  on  uric  acid  production 
because of its high guanosine content.
Pathogenesis
Uric acid is a weak acid (pKa 5.8) that is present mainly as urate, the ionized form, at 
physiologic pH. As urate concentrations increase in physiologic fluids, urate can crystallize as a 
monosodium salt in oversaturated tissues, mainly within and around joints, but also in the skin 
or other structures, such as spinal ligaments and fibrous tissue. The physiochemical properties 
of monosodium urate (MSU) cause crystals to precipitate in body fluids if the concentration is 
greater than 6.8 mg/dl. The solubility of urate is modulated by temperature (lower temperature 
at the foot), intra-articular fluid dehydration (onset at night), and cat ion concentration. MSU 
crystallization  is  dependent  on  nucleating  agents,  such  as  insoluble  collagens,  chondroitin 
sulfate,  proteoglycans,  cartilage  fragment,  and  other  crystals.  Tophus can  grow from urate 
crystals depending on urate super saturation and on increased promoters or loss of inhibitors of 
crystallization.
MSU crystals are capable of directly triggering, amplifying, and sustaining and intense 
inflammatory response, a so-called “acute attack, “because of their ability to activate humoral 
and cellular  inflammatory  components.  MSU crystals  first  are  released  in  the  joint  cavity, 
activating synovial lining cells, followed by the recruitment and activation of mastocyes and 
peripheral  blood  monocytes  through  endothelial  cell  activation.  Auto  limitation  of  acute 
inflammation is driven by macrophages, neutrophil necrosis, and apoptosis, followed in some 
cases by low - grade residual synovitis or by restitution ad integrum.
Initiation
Free  crystals  or  even  naked  crystals  with  no  protein  coating  are  released  form  a 
remodeling tophus. Once released within the joint cavity, under specific local and systemic 
circumstances temperature, pH variations, local articular trauma, infection, or surgery, MSU 
crystals should interact with the synovial lining cells. 
The  fibroblast-like  synoviocytes  and  macrophage-derived  cells,  has  phagocytic 
properties.  They  can  be  opsonized  by  proteins  and phagocytosed  as  particles,  triggering  a 
typical  phagocytic  inflammatory  response  .Initial  mechanism involves  the  physicochemical 
surface properties of MSU particles interacting directly within minutes with membrane proteins 
and  lipids,  either  physically  or  through  electrostatic  bounds  because  MSU  crystals  are 
negatively charged.
Membrane modulation leads to cross-linking and clustering of membrane as an initial 
event for activation of redundant signaling pathways, including G proteins, phospholipase C 
and D, tyrosine kinases associated with the FAK complex, and the three mitogen-activated 
protein kinases.
Crystal-induced cellular activation and recruitment
Neutrophils are the hallmark of inflammatory cells recruited into the synovial fluid in 
gouty attack; other cells also play a role.  Monocytes recruited from the blood and resident 
mastocytes are the first cells to infiltrate or be activated. Mast cells are proposed as plying a 
role in innate immunity and can be an important cell component of MSU CIA because they 
contain  preformed  granules  with  cytokines  and  also  histamine,  and  acute  phase  reagent. 
Histamine  is  well  documented  as  having  multiple  effects  leading  to  increased  vascular 
permeability  and enhanced adhesion molecule expression,  such as  up regulating P-selectin, 
which  medicates  neutrophil  adhesion  and  recruitments.   Preformed  and  stored  mastocyte 
mediators (e.g. platelet activating factor [PAF], vascular endothelial growth factor, TNF and 
IL-1  can  activate  endothelial  cells,  cell  recruitment,  and  increase  vascular  permeability. 
Monocytes also are implicated in the early onset of MSU CIA. They infiltrate the tissues of 
animal models of MSU CIA at a rate 10 times higher than neutrophils.
MSU crystals actually have the ability to trigger and inflammatory response by freshly 
isolated monocytes  and THP-1 monocytic  cells,  including TNF,  IL-1,  IL-6 and 8 (but  not 
IL-10) secretion, which in turn promote endothelial cell E-selectin expression and secondary 
neutrophil  adhesion  under  dynamic  conditions.  Angiogenic  factors  also  have  cytokine 
properties and are expressed in gout. High levels of angiogenin, an angiogenic factor with anti 
inflammatory properties, are measured in SF from patients who have gout. Monocytes play a 
central  role in the regulation of acute attack,  because they also are implicated in  the self-
limitation of inflammation.
Amplification
Neutrophils are recruited into synovium and migrate within the synovial cavity along 
with  serum  proteins.  Activated  endothelium  allows  neutrophil  adhesion  dependent  on  E- 
Selection and P-Selectin upregulation and migration into the synovium determined by effects 
of  cytokines  (TNF  and  IL-1∃)  and  chemokines  (IL-8  and  macrophage  inflammatory 
protein-1∃). Neutrophils follow concentration gradients of chemoattractants, such as C5a and 
IL-8.Spontaneous resolution of acute attack
Crystal properties can be modified and represent a first target: crystal size reduction and 
crystal clearance Macrophages (eg, resident and differentiated monocytes) should represent the 
major cell in this regulatory process. Mononuclear phagocyte may play a key role within the 
synovial compartment, tipping the balance from the asymptomatic state to acute inflammation, 
or vice versa, depending on the state of monocyte to macrophage differentiation. 
A switch from homologous monocytes to macrophages leads to the loss of ability to 
produce pro inflammatory cytokines (IL-1, I1-6,and TNF-α) and conversely, to stimulate anti-
inflammatory  cytokine  secretion  (IL-10  and  transforming  growth  factor  [TGF] ∃1)when 
stimulated  by  phagocytosed  MSU  crystals.  Under  MSU  crystal  stimulation,  macrophages 
produce IL-10 and, mainly, TGF-∃1, a pivotal cytokine in the anti-inflammatory process TGF-
∃1 can lower endothelial activation, reduce monocyte and neutophil adhesion and recruitment 
and reduce IL-1 expression and IL-1 receptor expression. 
TGF-∃1 secretion also can be triggered by ingestion of apoptotic cells. This monocyte-
macrophage switch and its ability to control inflammation a well-known mechanism not related 
specifically to MSU crystals.  The mechanisms underlying the anti-inflammatory switch are 
understood  but  it  seems,  for  example,  that  the  production  of  pro  and  anti  inflammatory 
cytokines by phagocytic monocytes is regulated delicately during the ingestion of apoptotic 
cells as part of an intrinsic mechanism to prevent inflammatory auto immune reaction. Binding 
or  phagocytosis  of  apoptotic  cells,  but  not  necrotic  or  lysed  cells  induce  active  anti-
inflammatory or suppressive properties in human macrophages.
It is likely that resolution of inflammation depends not only on the removal of apoptotic 
cells  but  also  on  active  suppression  of  inflammatory  mediator  production.  Other  anti-
inflammatory compounds also are released by MSU crystal stimulated macrophages, namely 
nitric  oxide  (NO)  and  peroxisome  proliferators  activated  receptor  (PPAR).NO  inhibition 
maintains the inflammatory cellular reaction evidenced in vivo.
Therefore  in  MSU-crystal  inflammation  NO  seems  to  act  as  an  anti  inflammatory 
compound. PPAR-c stimulation and production by adherent monocytes by MSU crystals can 
delay neutrophil apoptosis.
Intercritical gout
Although MSU crystals  are  the  hallmark of  gouty arthritis,  they  can be  found even 
during the resolution phase but have lost their ability to stimulate further inflammation, and 
also between attacks, because they remain in the joint.
Chronic tophaceous gout
After years of chronic and untreated hyperuricemia, gouty arthritis can develop with its 
hallmark, intra articular and periarticular tophi. Gout tophi are characterized by foreign body 
granulomas consisting of mono and multinucleated macrophages surrounding deposits of MSU 
microcystals. After primary formation, granulomas grow with degradation of the extra cellular 
matrix. Once developed in situ in cartilage or in synovium, it is assumed that MSU crystals 
may  contribute  to  chronic  synovitis  and  associated  joint  damage.  Tophi  can  grow  at  the 
cartilage surface and within the synovium, leading to low grade synovitis, even subsiding after 
clinical resolution of gout attacks or to foreign body synovitis around crystals, as evidenced by 
histologic studies. Direct cartilage-tophi contact is demonstrated by arthroscopy. Experimental 
studies related to topic pathogenesis are lacking. Immunohistochemistry studies performed on 
tophi show that perivascular localized mononuclear cells are CD68+,S100A8+, S100A9+, and 
24F9-, representing freshly migrated monocytes/macrophages. In contrast, almost all CD68+ 
mono-  and  multinucleated  cells  arranged  within  granulomas  are  S100A8-,  S100A9-,  and 
25F9+, representing mature (non migrating) macrophages. These macrophages coexpress TNF-
α, and matric metalloproteinases (MMPs) ,2 and 9. In parallel, macrophages undergo apoptosis, 
a  phenomenon  that  may  restrict  the  destructive  potential  of  inflammatory  macrophages. 
Corticosteroids could enhance tophus formation, as shown in the air pouch model by rull and 
colleagues and in clinical reports.
IMAGING GOUT
Radiographic examination in patients who have gout is used mainly to evaluate joint 
destruction and disease presence of tophi, and to help exclude other diagnoses. Radiographic 
findings may be categorized into the nonspecific changes that are seen in early gout, the subtle 
alteration of intercritical gout, and the more specific changes of chronic tophaceous gout. In the 
early stage of gout, the radiographs usually are normal or show nonspecific soft tissue swelling 
in the affected joint  secondary to synovitis,  capsular  disention,  and periarticular soft  tissue 
edema. As the attack subsides, the radiographic abnormalities usually disappear. Other causes 
of mono articular soft tissue swelling, including infection arthritis, pseudogout, and trauma, 
must be excluded. In the intercritical period, which occurs between the acute period and the 
development of chronic tophaceous gout, sutle joint alteration (eg. small, well-defined erosion) 
may be visualized at the periphery of affected joints
Characteristic  findings  occur  in  chronic  gout.  These  include  tophi,  erosions  with 
overhanging  edges,  relative  preservation  of  the  joint  space,  and  lack  of  osteopenia.  The 
hallmark  of  chronic  gout  is  the  presence  of  multiple  macroscopic  tophi  a  mixture  of 
monosodium  monohydrate  crystals  in  a  matrix  of  amorphous  debris  containing  urate, 
proteinaceous deposits, and lipids with a surrounding foreign body reaction. Generally, they are 
ovoid and asymmetric and usually are radio graphically invisible until they reach 5 mm to 10 
mm in diameter. Large tophi may be palpable. Faint calcification may occur in up to 50 percent 
of tophi. However, cloud like masses of densely calcified tophi is atypical and may reflect a 
coexisting abnormality of calcium metabolism, such as renal insufficiency. Erosion in chronic 
gout is common and usually is associated closely with the tophaceous deposits because the 
erosion may occur secondary to chronic pressure from the adjacent tophus. When characteristic 
erosion is  seen along with tophi  the  diagnosis  of  gout  is  almost  certain.  Frequently,  these 
erosions are round or oval in shape and well circumscribed, and typically are eccentric and 
oriented along the axis of bone. Most often they are juxta-articular but may be intra articular or 
located at a distance form the joint. Intra-articular erosions tend to involve the joint margins 
before extending to the middle of the joint. Interosseous erosions may have sclerotic borders 
that produce a punched-out appearance.
A characteristic feature of gouty erosions is the overhanging edge, and elevated margin 
of  bone  that  extends  over  the  expected  confines  of  the  cortex  at  the  site  of  erosion.  The 
overhanging edge is seen in approximately 40percent of patients who have tophaceous gout and 
may  represent  new  bone  formation  around  a  gradually  enlarging  tophus.  Occasionally, 
extensive  osseous  erosions  produce  a  mutilating  arthritis  that  mimics  the  opera-glass  hand 
deformity that is seen occasionally with rheumatoid or psoriatic arthritis.
The joint space is relatively well preserved, even in the presence of extensive juxta - 
articular erosions. Large tophi are an important radiographic feature the helps to differentiate 
gout form other causes of arthritis.  If  joint space narrowing has occurred,  the radiographic 
appearance  may  mimic  the  uniform  narrowing  of  rheumatoid  arthritis  or  advanced 
osteoarthritis (OA). However, patient who have joint space narrowing generally have had long 
- standing disease and the clinical diagnosis of gout already is well established.  Ankylosis with 
obliteration of the joint space is rare. Osteopenia is an atypical feature of gout. When bone 
density is diminished in long-standing gouty arthritis, disuse is believed to be the cause & may 
be  seen  during  an  acute  gouty  attack,  presumably  from  inflammation-induced  hyperemia. 
However, this is transient and the bone density tends to be preserved, even in advanced chronic 
gout with articular destruction. In frequently, a zone of osteoporosis in the sub chondral bone 
may progress to a cystic abnormality. Interosseous tophi and sub chondral cysts may mimic 
focal osteoporosis and should not be confused with diffuse periaticular ostepenia.
Localized increase bone density may be seen in a minority of patients (-6percent) that 
has advance tophaceous gout, predominantly in the hands and feet. The increased bone density 
may  represent  calcification  of  interosseous  monosodium urate  deposits.  The  radio  graphic 
appearance  may  resemble  an  area  of  bone  infarction  or  enchondroma.  Occasionally,  bone 
proliferation is present in gouty arthritis. Enlargement of the ends and shafts of involved bones 
can produce club-shaped metatarsal and phalangeal heads. This is termed as“mushrooming.” 
Irregular bone spicules are noticed at the site of muscle /tendon insertion of the bones such as 
calcaneus,  olecranon,  and  patella.  A  fine  lacy  periosteal  new  bone  formation  may  form 
secondary  to  periosteal  reaction  that  is  caused  by  cortical  destruction  by  adjacent  crystal 
deposition, and often, this is best seen on the medial aspect of the first MTP joint. Bilateral 
olecranon bursitis is charactersitic feature of a gouty arthritis.
Hyperuricemic  patient  may  present  with  urinary  calculi  before  developing  gouty 
arthritis.  A non-contrast CT scan performed with thin slices (3-5 mm) through the urinary-
collecting system has replaced intravenous urography as the gold standard for detecting urinary 
calculi, which can detect urate stones as small as 2 mm without much of difficulty. CT rarely is 
useful  in  patients  who have gout  other  than for  the  detection of  urinary  calculi.  Although 
several papers have described MRI findings in patients who have gout, MRI is not used as a 
routine diagnostic tool.
TREATMENT
The therapeutic aims in gout are as follows:
 To terminate the acute attack as promptly and gently as possible.
 To prevent recurrences of acute gouty arthritis 
 To prevent or reverse complications of the disease resulting from deposition of sodium 
urate or uric acid crystals in joints, kidney, or other sites.
 To prevent or reverse associated features of the illness that are deleterious, such a obesity, 
hypertriglycerdemia, and hypertension. The time of initiation of therapy is more important 
then the choice of drug. With any choice of drug. With any of these agents, the sooner the 
drug is started, the more rapidly a complete response will be attained generally, colchicine 
is preferred for patients in whom the diagnosis of gout is not confirmed, whereas NSAIDs 
are preferred when the diagnosis is secure. If a patient cannot take medications orally due to 
active  peptic  ulcer  disease,  the  other  options  are  intravenous  colchicines,  intra-articular 
glucocorticoid or parentral glucocorticoids. Local application of ice packs may help control 
the pain of an acute attack. In some cases, analgesics, including narcotics, may be added as 
well.  The  commonest  cause  of  difficulty  in  controlling  an  attack  is  the  simultaneous 
administration  (or  withdrawal)  of  drugs  that  alter  the  plasma urate  concentration.  Both 
increases and decreases in the plasma urate concentration may precipitate or prolong an 
attack of gout. Therefore, therapy aimed at reducing urate concentrations should be delayed 
until the complete resolution of all signs of inflammation. However, should the patient be 
stabilized on a constant dose of a urate - lowering drug at the time of an acute attack, the 
urate-lowering  drug  should  be  continued  at  the  same  dose  until  specific  treatment  has 
caused the acute gout to subside.
Colchicine
Colchicine is an alkaloid derived form the autumn crocus Colchicum autumn ale. It has 
an anti-inflammatory action in acute attacks of gout and a prophylactic effect against recurrent 
attacks. It has no effect on the serum urate concentration or on urate metabolism. Colchicine 
derives its effectiveness from its ability to interfere with acute inflammatory reactions in a 
variety  of  ways  many  of  them  mediated  through  the  effects  on  neutrophil  microtubules. 
Colchicine inhibits E-Selectin-mediated adhesiveness of neutrophils and diminishes neutrophil 
L-selection expression, random motility, chemotaxis, PLA activation, and IL - 1 expression, as 
well  as  the  stimulated  elaboration  of  PLAF (Platelet-activating  factor)  and  the  chemotatic 
factors CCF and LTB4. Colchicine also inhibits endothelial cell ICAM- expression, mast cell 
histamine release, and down regulates TNF-a receptors on macrophages and endothelial cells.
Colchicine can be administered by oral or intravenous routes 
Orally, a dose of 0.5 or 0.6 mg is taken hourly until one of three things occurs: 1) Joint 
symptoms  ease;  2)  nausea,  vomiting,  or  diarrhea  develops;  or  3)  the  patient  has  taken  a 
maximum of 10 doses. If 10 doses are taken without benefit, the clinician should question the 
accuracy  of  the  diagnosis.  Peak  plasma  concentrations  occur  within  2  hours  of  oral 
administration.  Although,  the  plasma  half-life  of  colchicine  is  only  4  hours  after  oral 
administration, colchicine levels can be detected in neutrophils even 10 days after ingestion. 
Colchicine has a low therapeutic index with steady-state plasma concentration ranging between 
0.5  and  3.0  ng/ml  following  an  acute  treatment.  At  the  same  time  the  toxic  effects  of 
colchicines can occur even at a concentration of 3 ng/ml. Therefore, in most patients, the side 
effects precede or coincide with improvement in joint symptoms. These side effects develop in 
50  to  80  percent  of  patients  and  include  increased  peristalsis,  cramping  abdominal  pain, 
diarrhea,  nausea,  or  vomiting.  The  drug  must  be  stopped  promptly  at  the  first  sign  of 
gastrointestinal side effects.
Colchicine can also be given intravenously. When used properly, the drug abolishes the 
acute attack with a low incidence of gastrointestinal side effect (Provided that the patient is not 
also taking colchicines by mouth). An initial dose of 1 or 2 mg can be followed by one or two 
additional 1 -mg doses administered at 6 hour intervals, if needed. The total dose of intravenous 
colchicines should not exceed 4 mg. The colchicines should be diluted with 20ml of normal 
saline before administration and given slowly into an established venous access to minimize 
sclerosis of the vein. 
In addition, oral colchicines should be discontinued and no additional colchicines should 
be given for at least 7 days because of the slow excretion of this drug.
The use of intravenous colchicines is  associated with some risk.  The most common 
complication is  local extravasations during or immediately after injection. This can lead to 
inflammation and necrosis and may be extremely painful. The drug should not be given to 
patient who are neutropenic or to those with significant liver or renal disease. Although this 
form of therapy is effective, the reports of severe toxicity and death caused by inappropriate 
use of the medication are too plentiful.
Non steroidal anti-inflammatory drugs
In the patient with an established diagnosis of uncomplicated gout, the preferred agent 
of choice is an NSAID. Indomethacin has been the traditional choice of agents in this class. 
Although this drug may be effective in doses as low as 25 mg given four times a day, an initial 
dose of 50 to 75mg, followed by 50 mg every 6 to 8 hours with a maximum dose of 200mg in 
the first 24 hours, has generally been recommended. To prevent relapse, it is reasonable to 
continue this does for an additional 24 hours, and then taper to 50 mg every 4 to 8 hours for the 
next 2 days. Clinical trials have also shown that oral naproxen, fenoprofen, ibuprofen, sulindac, 
piroxicam, and ketoprofen, as well as intramuscular ketorolac, are also effective. In fact all 
members of this family of drugs can be highly effective in the treatment of acute gouty arthritis, 
including the cyclooxygenase-2 (COX-2) selective agents.
Glucocorticoids
Intra-articular glucocorticoids are useful in the treatment of acute gout limited to a single 
joint  or  bursa.  Oral  glucocorticoid  usage  along with  a  single  intramuscular  or  intravenous 
injection of a parentral   glucocorticoid can also provide relief. Anecdotally, rebound attacks 
have been reported as steroids were withdrawn. ACTH has been used effectively, especially in 
attacks in patients following surgery.
Prophylaxis
The practice of giving small daily doses of colchicines as prophylaxis to prevent acute 
attacks up is proven to be effective. The use of colchicines at 0.6 mg once to three times a day 
is  generally  well  tolerated,  although  the  drug  may  produce  a  reversible  axonal  neuron 
myopathy.  In  patients  who  are  unable  to  tolerate  even  one  colchicine  tablet  per  day, 
indomethacin  or  another  NSAID  can  been  used  prophylactically  at  low  doses  (e.g.,  25 
indomethacin  b.i.d)  with  some  success.  A  program  of  maintenance  with  colchicines  or  a 
NSAID may make difference by avoiding frequent incapacitation and facilitating uninterrupted 
daily  activities.  Prophylaxis  usually  is  continued  until  the  serum  urate  levels  have  been 
maintained well with in the normal range and there have been no acute attacks for a period of 3 
to  6  months.  It  is  important  to  warn patients  that    discontinuation of  colchicines  may be 
followed by an exacerbation of acute gouty arthritis. Prophylactic colchicines may block the 
acute inflammatory response but does not alter the deposition without of crystals in tissues. 
With continued deposition without the warning signs of recurrent bout of acute arthritis, 
tophi and destruction to cartilage and bone can occur without notice.
Correction of the causes of hyperuricemia
Prevention of gout is  directed at  restoring the plasma urate concentration to normal. 
Many factors contributing to an elevation of urate concentration have been recognized and a 
number of  these  factors  can be  identified in  individual  patients  with gout.  Factors  already 
identified  as  contributing  to  hyperuricemia  include  the  syndrome  of  obesity, 
hypertriglyceridemia, hypertension and insulin resistance, which is an increasing public health 
and nutritional  problem in  western societies.  Correction of  obesity  can  cause  remission  of 
hyperuricemia and even a moderate loss of weight can facilitate the renal excretion of urate. 
However, the necessary changes in lifestyle and diet are rarely maintained long term, although 
increasing community recognition of the need to maintain a healthy lifestyle may help this in 
the future. In addition, diuretic therapy or inadequately treated hypertension will contribute to 
hyperuricemia.
A  high  purine  intake  will  also  contribute.  Although,  high  purine  foods  are  well-
recognized contributors, it is less commonly appreciated that a large helping of a food with a 
medium concentration of purines may provides a much larger purine load than a small helping 
of a food high in purines. Moderation of purine intake and avoidance of high purine foods is 
desirable in most patients with gout, particularly if there is any difficulty in achieving a normal 
plasma urate.
Dietary restriction of purines rarely causes a fall in the plasma urate concentration of 
more than 1.0 mg/dl (o.o6mmol/l) unless the diet has had large purine content. Moreover, such 
dietary restriction can rarely be sustained for long and is only occasionally clinically useful.
Antihyperuricemic drugs provide a definitive method for controlling hyperuricemia .In 
general the lower the serum urate level achieved during anti hyperuricemic therapy, the faster 
the  reduction  in  tophaceous  deposits.  Reduction  to  target  level  may  be  achieved 
pharmacologically by the use of xanthine oxdase inhibitors or uricosuric agents. Once initiated, 
the use of antihyperuricemic agent is ordinarily carried on indefinitely for those patients with 
gout  who excrete  less  than  800 mg of  uric  acid  per  day  and have  normal  renal  function. 
Reduction of serum urate concentration can be achieved equally well with a xanthine oxidase 
inhibitor or a uricosuric drug. These agents are equally effective n preventing deterioration of 
renal function in patients with primary gout. In most cases, allopurinol is probably the drug of 
choice because it can be used with fewer restriction compared to uricosuric agents.
In general, the candidate for uricosuric agents is the gouty patient who is younger than 
60 years of age and has normal renal function uric acid excretion of less than 800 mg/24 hours 
on a general  diet,  and no history of renal  calculi.  Probenecid is  readily  absorbed from the 
gastrointestinal tact. Its half-life in plasma is dose dependent varying from 6 to 12 hours. This 
can be prolonged by the concomitant use of allopurinol. 
The  maintenance  dosage  of  probenecid  ranges  from 500 mg to  3  g  per  day  and is 
administered on a twice or three times a day schedule. Acute gouty attacks may accompany the 
initiation of this medication, as with medication, as with all other antihyperuricemic agents, 
and, as with all uricosuric agents, patients using probenecid are at increased risk for developing 
renal calculi Sulfinpyrazone is completely absorbed from the gastrointestinal tract and has a 
half-life  of  1  to  3  hours.  Most  of  the  drug  is  excreted  in  the  urine  as  the 
parahydroxylmetabolite, which is also uricosuric. Sulfinpyrazone is maintained at a daily dosed 
300-400mg per day in three to four divided doses Benzbromarone is a potent uricosuric agent 
and can be used with moderate renal dysfunction. Patients’ prescribed with  uricosuric agent 
should be counseled to avoid salicylate use at doses greater than 81 mg per day.
In certain situations, an inhibitor of xanthine oxidase is clearly the drug of choice in the 
gouty patient. Gouty individuals who excrete larger quantities of uric acid in their urine or who 
have a history of renal calculi of any type should be treated with allopurinol. The incidence of 
renal calculi is  about 35 percent in patients with primary gout who excrete more than 700 
mg/day of uric acid. Allopurinol is converted to oxipurinol an inhibitor of xanthine oxidase. 
Allopurinol is metabolized in the liver and has a half-life of 1 to 3 hours, but oxipurinol, which 
is excreted in the urine, has a half-life of 12 to 17 hours. Because of these pharmacokinetic 
properties, allopurinol is dosed on a daily basis, and the dosage required to reduce serum urate 
levels is lower in patients with decreased glomerular filtration rates .Allopurinol should be used 
at the lowest dose that lower the serum urate level below 6 mg/dl. This most often achieved 
with doses of 300 mg per day, but a maximum of 800  mg can be used The sudden lowering of 
serum urate concentrations that accompanies initiation of allopurinol therapy may trigger acute 
gout attacks. This risk can be minimized by beginning prophylactic colchicines or NSAID two 
weeks before the first dose of allopurinol. As an alternative, allopurinol can be started at a dose 
of 100mg per day and increased by 100 mg increments on a weekly basis. Around 20 percent 
of patients who take allopurinol report side effects, with 5 percent of patents discontinuing the 
medication. The side effects are gastro intestinal intolerance, skin rash, alopecia, bone marrow 
suppression  with  leucopenia  or  thrombocytopenia,  agranulocytosis,  aplastic  anemia, 
granulomatous  hepatitis,  jaundice,  sarcoid  like  reaction,  and  vasculitis.  Allopurinol  will 
potentiate  the  action  of  other  agents  that  are  inactivated  by  xanthine  oxidase,  the  most 
important of them are azathioprine and 6-mercaptopurine. 
REVIEW OF LITERATURE
Epidemiologic data suggest that the overall disease burden of gout remains substantial 
and may be increasing.  The national  arthritis  data  work  group reviewed earlier  population 
based studies that estimated the prevalence of gout, such as Tecumseh community health study, 
the Framingham heart study and the Sudbury study. According to the most recent available 
national health interview survey (NHIS), data on self reported gout from the 1996 survey, the 
overall prevalence for the one year period was 9.4 cases per 1000persons in the United States. 
The prevalence increased with age from 1.8 per 1000 aged 18-44 to 33.5 per 1000 in persons 
aged 45-64 &46.4 per 1000 in persons aged 65 and older.
In the NHANES III (the national health &nutritional examination survey) the life time 
prevalence of gout was lowest (0.4%) in subjects aged 20-29, 11.6% in those aged 70 to 79. 
Although gout was reported more often in men than in women the overall prevalence in women 
approached that of men after menopause. The prevalence of gout was 3.2 percent in women 
aged 60 to 69 and increased to 5.2 percent in women aged 70 to 79 and 5.3 percent in women 
aged 80 years and older. 
Data suggest that the prevalence of gout is increasing .Lawrence et al (5) reported a 
doubling of the prevalence. The steepest increase occurred between 1969 and 1976. Wallace et 
al (84) reported that the overall prevalence of gout and hyperuricemia requiring serum urate 
lowering medication had increased by 80 percent in 1999 as compared with that in 1990. Zeng 
et  al  (6)  also  reported  a  similarly  increasing  trend  in  Chinese  population  in  1990’s.The 
Rochester Epidemiology project identified cases of new gout at an incidence rate of 45 per 1, 
00,000 for the 2 year interval 1977 to 1978, which during the 1995-1996 was 62.3 per 1000, a 
greater than two fold increase in the rate of primary gout during the 20 year period. Choi et al 
(7) reported increase in incidence and prevalence of primary gout with age in men and women. 
Aromadee et al (8) has reported a doubling in the incidence of primary gout in the past 20 
years.
Campion et al (9) in the normative aging study evaluated the incidence of gout stratified 
by prior uric acid levels. Based on 84 incident  cases of gout during a 15 year period, the all 
male study found the annual incidence of gout  was less than 0.1 percent for men who had 
serum  uric  acid  less  than  7mg/dl,  0.4percent  for  7-7.9mg/dl,  0.8percentfor  8-8.9mg/dl, 
4.3percent for  9-9.9mg/dl and 7 percent for greater than 10mg/dl. Lin et al(10)studied men 
with hyperuricemia in a Chinese population for a 5 year period .42 cases of incident gout were 
documented .Annual incidence rates of gout in this study were 2.2percent  for 7-7.9mg/dl ,
5.5percent for 8-8.9mg/dl and 12.2 percent for greater than or equal to 9mg/dl. No data on the 
impact of prior uric acid levels on incident gout specifically in women are available. This study 
also showed significant associations with obesity,  alcohol consumption and diuretic use for 
hypertension independent of uric acid levels.  The study also found a significant interaction 
between persistent  alcohol  consumption and baseline  uric  acid levels  in  the  hyperuricemic 
range.
Roubenoff et al (11) reported that increased BMI at age 35 but not at base line was 
associated with the risk of gout. Abbot et al (12) found a significantly higher BMI in patients 
who  had  gout  after  adjusting  for  age.  Choi  et  al  (14)  compared  men  who  had  BMI 
21-22.9kg/m, the multivariate  RR of  gout  were 1.95(1.44-2.65)  for  men who had BMI 25 
to29.9kg/m, 2.33(1.62-3.36) for 30 to 34.9kg/m and 2.97(1.73 -5.1) for greater than35kg/sq.m. 
The multivariate RR for gout in men in the highest waist to hip ratio quintile (0.98 -1.39) 
compared with those in the lowest (0.70-0.88) was 1.82(95 percent CI, 1.39-2.39). Emmerson 
et al (13) compared men who maintained their weight since age 21, the multivariate RR of gout 
for men who gained 30 pounds or more was 1.99(1.49-2.66). In contrast the multivariate RR 
for men who lost 10 pounds or more was since the study baseline was 0.61.Increased adiposity 
leads to hyperuricemia via increased production and decreased renal excretion of urate.
Choi et al (14) reported increasing alcohol intake associated with increasing risk for gout 
(a dose response relationship).Compared with men who did not drink alcohol, the multivariate 
RR of gout increased from 1.25 for alcohol consumption to 2.53 (>50g/day).This risk varied 
substantially (5-9.9g/day) according to the type of alcohol beverage .Beer conferred a larger 
risk than liquor whereas moderate wine drinking did not increase the risk. 
Graham et al (15) studied that the high prevalence of hypertension in patients who have 
classical gout is related more closely to obesity rather than the duration of gout. Prebis et al 
(16)states  that renal uric acid clearance  depends on the  tubular secretory and post secretory 
reabsorption rates which was found to be lower relative to glomerular filtration rates in both the 
adult and childhood hypertensives and this correlated to the renal blood flow. 
Messerli et al(17) in the study on serum uric acid in essential hypertension states that 
selectively increased renal and peripheral vascular resistance  are documented in subjects who 
have essential hypertension with hyperuricemia raising the possibility that hyperuricemia is a 
consequence of early nephrosclerosis in  patients who have essential hypertension. Kanellis et 
al  (18)  states  that  the  urate  stimulates  monocyte  chemoattactant  protein-1  production  in 
vascular smooth muscle via mitogen activated protein kinase and cyclooxygenase2. Mazzali et 
al (19) demonstrated an increase in juxtaglomerular renin content and decreased macula densa 
neuronal nitric oxidesynthase content, implicating the mediating systems in the regulation of 
blood  pressure.  The  preglomerular  arteriopathy  accompanying  these  changes  accounts  for 
development of a salt sensitive hypertensive state, not reversible by lowering of serum urate 
levels. 
Feig and Johnson et  al  (20)  demonstrated a linear  relationship between serum urate 
levels and systolic blood pressure in adolescents who have new onset hypertension .Segura et al 
(21) reported urate levels to correlate development of chronic renal insufficiency in patients 
who have hypertension. Leoncini et al (22) reported higher serum urate levels in those who 
have renal impairment. Johnson et al (23) supports the view that hyperuricemia is an important 
risk factor for ischemic heart disease  and  other  forms of   cardiovascular  disease.
Brand et al predicted hyperuricemia  as  a  risk  factor  for  coronary  artery  disease 
.Nagahama  et  al(25)  has  reported  clustering  of  hyperuricemia  with  cardiovascular  risk 
factors  .Fang  J  et  al(26)  reported  increasing  serum  urate  concentration   was  related  to 
increasing cardiovascular mortality in both sexes and in blacks and whites. 
Rich M Wet al (27) reported that serum urate levels >/=6 mg/dl were found to be an 
independent  predictor  of  coronary  artery  disease.  Hoieggen  et  al  (28)  in  the  LIFE  study 
reported a significant association between baseline serum urate level and risk for a morbid or 
fatal  cardiovascular  event.  The  risks  of  recurrent  coronary  disease  events  were  correlated 
significantly with serum urate levels such that the serum urate was regarded as an independent 
predictor  of  recurrent  coronary  heart  disease  events.  Mercuro  et  al  (29)  suggested  that 
restoration of  normal  serum urate  by allopurinol  300mg daily  improves  the flow mediated 
dilatation aspect of vascular function. Madsen et al (30) reported that higher serum urate levels 
are predictors  of  mortality  in  patients  with  significant  angiographically  defined  coronary 
artery  disease. 
Lehto et al(31) found hyperuricemia as a predictor hazard of nonfatal and fatal stroke in 
a population based study of middle aged NIDDM. Mazza et al (32) in the CASTEL study 
(cardiovascular study in the elderly) reported serum urate as an independent predictor of stroke 
mortality, poor outcome and subsequent vascular events especially in diabetics. Abuja et al 
( 33)studied that the levels of antioxidants such as ascorbate are reduced immediately after 
acute  ischemic  strokes  .Patients  who have  the  worst  outcomes  are  those  who have  higher 
plasma urate levels raising the speculation  that under circumstances of  alternative antioxidant 
depletion urate may become pro oxidant. 
Tseng et al (34)identified hypertension as a significant and independent risk factor for 
peripheral arterial disease in Taiwanese men who have type 2 diabetes mellitus and also for 
carotid  atherosclerosis  .Neuto  et  al  (35)  in  their  prospective  case  controlled  study  found 
baseline serum urate levels associated significantly and independently with increased coronary 
atherosclerosis(13 years later).
Hare et al (36 )study suggests urate as a strong contributor to more severe heart failure 
through its role in hypertension. Capola et al (37) demonstrated evidence for direct and indirect 
pathophsiologic roles of abnormal urate metabolism in congestive heart failure. Ekelund et al 
(38) demonstrated that allopurinol decreases myocardial oxygen consumption. Ukai et al (39) 
reported  that  allopurinol  improves  systolic  function  in  patients  of  congestive  heart  failure. 
Doehner et al (40) proposed that endothelial damage resulting from xanthine oxidase generated 
oxygen free radicals as a basis of cardiac dysfunction in hyperuricemic states and allopurinol 
inhibition of xanthine oxidase is reported to improve endothelial dysfunction in patients who 
have heart failure. 
Denzer et al (41) reported that serum urate levels contribute significantly to levels of 
HDL cholesterol, total cholesterol, BMI and systolic pressure in children and adults who are 
obese  and may  be  a  reliable  marker  of  “Premetabolic  syndrome”.  Vuorin  –Markkola(42  ) 
found the inverse correlation of serum urate and insulin sensitivity and the positive correlation 
of urate and triglceride in 50 percent .Also suggested that hyperuricemia may be used as a 
simple marker of insulin resistance. 
Emmerson et al (43) studied that weight reduction is associated with a modest lowering 
of serum urate concentration and decrease in rate of de novo purine biosynthesis. Dessein et al 
(44) stated that the weight loss associated with moderate calorie and carbohydrate restriction 
and increased proportional intake of protein and unsaturated fat is accompanied by a decrease 
in  seum urate  levels  and  dyslipidemia  in  patients  who have  gout.  Tsunoda  et  al  (45)  has 
demonstrated amelioration of insulin resistance by a low energy diet that decreases serum urate 
levels in individuals who are hypertensive and overweight. 
Donahue et al (46) found most obese persons to show leptin resistance and inceased 
leptin levels to be associated with leptin resistance in individuals who are non diabetic. Ruige 
et  al  (47)  found that  insulin  response,  triglceride  levels  and BMI to  be  independently  and 
significantly associated with leptin concentration. Ogura et al (48) found correlation of serum 
urate and leptin in healthy male adolescent. Garcia et al (49) found the correlation of serum 
urate and leptin in moderately obese women.
Bedir et al (50) studied that creatinine, leptin insulin and triglceride levels accounted for 
the variability in serum urate in men and women. Serum urate, obesity and insulin resistance 
may be mediated atleast in part by leptin expression and that leptin levels may prove to be a 
link between obesity and hyperuricemia.
Daskalipoulou et al (51) reported that in humans fasting serum triglyceride may be the 
most important determinant of serum urate levels. Takahashi et al (52) found no association 
between gout and HDL levels or BMI suggesting that decreased HDL levels are attributed to 
altered  triglyceride  metabolism.  Cardona  et  al  (53)  studied  that  the  prevalence  of 
apolipoproteinE2 allele was greater in patients who had gout and its presence was associated 
with higher triglyceride levels in very low density and intermediate density lipoprotein and 
with reduced renal uric acid excretion.
Yuorrin-Markkola et al (42) studied the relationship between hyperuricemia and insulin 
resistance  and  suggested  that  it  might  be  indirect  and  mediated  through  fasting  plasma 
triglyceride levels. Rocic et al (54) reported that in experimental animals urate suppresses basal 
insulin release and inhibits glucose stimulated insulin secretion. Facchini et al (55) in a study of 
the relationship of insulin mediated glucose disposal and serum urate in 36 healthy non diabetic 
volunteers  found renal  uric  acid clearance to be reduced in proportion to increased insulin 
resistance  resulting  in  increased  serum  urate  concentration.  Yuorrin-Markkola  et  al  also 
reported the association between hyperinsulinemia and reduced uric acid clearance. 
Lin and Chou et al (56) studied that persistent hyperuricemia in postmenopausal state is 
associated with subsequent development of  diabetes.  Nakanishi  et  al  (57)  in a longitudinal 
study on Japanese male office workers found the strong association between serum urate and 
hypertension and /or type2 diabetes mellitus. The relationship with diabetes was stronger in 
men who had a BMI of less than 24kg/m compared with higher BMI but the absolute risk was 
greater in more men who were obese. Gockcel et al (58) reported that metformin administered 
not only reduces post prandial and fasting blood glucose levels but also serum urate levels.
LiuBryan et al (59) have described toll like receptorTLR2 andTLR4 on the cell surface 
which has been implicated in chondrocyte and macrophage signaling.  Murakami et  al(60 ) 
reported that monosodium urate crystals could  induce rapidly  on neutrophils the  expression 
of  trigerring   receptors  expressed  on myeloid  ce4lls(TREM).Ryckman et  al(61  )  identified 
factors like meloid related protein in the mediation of  acute monosodium urate crystal induced 
inflammation.
Tramoniti et al (62) identified complement membrane attack complex as the mediator of 
acute attack. Inokuchi et al (63) reported   IL-8 to be increased in the plasma from patients who 
have  gouty  arthritis  which  was  secreted  by  monocytes  after  monosodium  urate  crystal 
stimulation along with an activation of caspase-1 the processing enzyme for IL-8 activation. 
Neutrophil apoptosis is advocated as a possible mechanism for resolution of an acute attack. 
Huyn and Fadok et al (64) stated that apoptotic cell recognition and clearance via exposure of 
phosphatidylserine and ligation of its receptor induce TGF B secretion resulting in acclerated 
resolution of inflammation.
Pascal et al (65) identified monosodium urate crystals in synovial fluid taken from the 
first metatarsal or knee joint of asymtomatic patients with proven gout during the intercritical 
period.  He  also  reported  that  treatment  with  colchicine  decreases  white  cell  counts  in  the 
synovial fluid of asymptomatic knee that contain monosodium urate crystals. Liu et al (66) 
studied that chondrocytes can phagocytose particles and in vitro non adherent chondrocytes can 
produce active MMP, S after monosodium urate crystal stimulation.
Liu Bryan(67) et al studied that direct chondrocyte cell membrane crystal can trigger 
cell  activation  ,NO  synthase  expression  and  NO  production,IL-1B  activation  and  MMP 
expression which can contribute to cartilage degradation and further tophus breaking. Bouchard 
et al (68) reported that monosodium urate crystals contribute to bone lesions and MSU crystals 
reduce the activity of osteoblasts in vitro thereby limiting the healing process of erosions.
 Vandiver et al (69) observed that defect in anti-inflammatory properties of macrophages 
could contribute to low grade inflammation by residual MSU crystals. LiotiF et al(70 ) has 
identified  ultrasound as  a  promising  new modality  for  gout.  Koski  et  al  (71)  reported the 
frequent finding of small fluid collections in the first MTP joints. Thiele and Schleisinger et al 
(72) in a study of 23 patients of gout found ultrasound to detect early gouty erosion. They also 
demonstrated the sensitivity of ultrasound in the detection of calcification of hyaline articular 
cartilage.
 Becker et al ( 73)in a recent study of 762 patients of gout compared the effects of 
allopurinol(300  mg  daily)  with  febuxostat  a  new  xanthine  oxidase  inhibitor(80mg  &  120 
mg).The primary end point (a serum urate <6mg/dl)was achieved in only 21 percent of the 
patients  receiving allopurinol  compared with 53 percent  of  the  patients  receiving 80mg of 
febuxostat and 62 percent of those receiving 120mg/day of feboxostat .He also reported that 
febuxostat is safe and effective in lowering serum uric acid levels in patients who have gout 
and hyperuricemia, safe and more effective  in maintaining serum urate levels.
Wortman (74) et al reported that febuxostat is more effective in reducing the size of 
tophi during 12 months. Moolenberg et al (75) has reported that rasburicase given by repeated 
intravenous  injection  had  good  effect  in  cases  of  tophaceous  gout  resistant  to  combined 
treatment with allopurinol and benzobromarone. Sundy et al (76) in an open labeled phase 2 
study found that use of multiple intravenous injections of PEG uricase in severe refractory gout 
confirmed sustained and substantial reduction of serum urate. Baraf (77) et al observed rapid 
resolution of tophi within three months in two patients following PEG uricase therapy. 
AIM OF THE STUDY
 To study the epidemiological characteristics of various patients of gout.
 To study the musculoskeletal features and biochemical characteristics in them.
 To analyze the comorbidities in these patients.
MATERIALS
Seventy consecutive patients of gout who attended the department of 
rheumatology, Madras Medical College were included in the study. 
This  is  a  Prospective    Study  conducted  between  January  2006  and 
March 2008.
INCLUSION CRITERIA
A  definitive  diagnosis  of  gout  was  established  by  demonstration  of 
intracellular  uric  acid crystals  in  the  synovial  fluid  or  tophi.  When crystals 
could  not  be  demonstrated  diagnosis  was  established  if  six  of  the  twelve 
American rheumatism association (ACR) criteria were fulfilled.
EXCLUSION CRITERIA
Patients of psoriasis, Systemic lupus erythematosus and hematological 
malignancies with elevated uric acid levels were excluded from the study.
METHODS
All  patients  were  asked  for  a  detailed  history  which  includes  the 
duration of the disease, disease onset, the first joint affected, the duration of the 
attack,  the  time  interval  between  subsequent  episodes,  whether  it  was  a 
persistent arthritis, and time of onset of first MTP joint involvement .A history 
of  other  illnesses  such  as  coronary  artery  disease,  hypertension, 
hypothyroidism and consumption of alcohol was asked for. A detailed general 
examination,  height,  weight  and  body  mass  index  was  calculated.  A 
musculoskeletal system examination and other systems were done. 
Hematological evaluation included complete hemogram and peripheral 
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smear.  Biochemical  parameters  including  blood  glucose,  urea,  serum 
creatinine,  liver function test,  fasting lipid profile,  serum uric acid,  24 hour 
urinary uric acid excretion and synovial fluid analysis for monosodium urate 
crystals were done.
Ultrasound of  abdomen was done with reference to  fatty  liver,  renal 
abnormalities, renal calculi, renal cyst, and features of medical renal disease. 
USG assessment of Intimomedial thickness of the carotid arteries was done in 
50 patients. Plain x-rays of the involved joints were taken. CT scan of the feet 
was done in four patients and hands done in one.
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RESULTS
AGE & SEX
Seventy patients of gout were analyzed of which 57 were males and 13 
were females. Five   patients  belonged  to  the group  of  young  onset  gout (< 
30 Yrs) and  all of them were  males. The mean age of patients of  young  onset 
was  25.3 ± 5.08 yrs.  with  a  't'   value  of  4.966  which  was  of  high 
statistical  significance. The mean age of males in late onset group was 45.32 ± 
11.65 yrs. and females was 48 ± 7.93 yrs. There was no statistically significant 
difference in  age  distribution  among  sexes (t  value  of  0.788). 38 patients 
(55.5%) gave history of alcohol consumption, of which 37 are males. 
AGE DISTRIBUTION OF PATIENTS OF GOUT
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TABLE 1: MEAN AGE OF PATIENTS OF GOUT
Age Male (Age in yrs) Female 
(Age in yrs)
Total
 (Age in Yrs)
Young <30 yrs 25.4±5.08 0 25±5.08
Adult >31 47.23±10.22 48±7.93 47.38±9.75
Total 45.32±11.65 48+7.93
TABLE 2: FEMALES IN COMPARISON  TO MALES
Males Females
Number of patients 57(81.4%) 13(18.6%)
Age  in  yrs 45.32±11.65 48±7.93
Duration in yrs. 4.36±4.01 2.08±1.43
Pattern of arthritis
Polyarthritis
Oligoarthritis
Bursitis
1st MTP
43(75.4%)
13(22.82%)
1(1.75%)
48(84.2%)
9(69.23%)
4(30.77%)
0
8(61.5%)
Tophi 18(31.57%) 2(15.4%)
Hypertension 35(61.4%) 8(61.5%)
Diabetes Mellitus 4(7%) 2(15.3%)
Coronary Artery diseases 7(12.3%) 1(7.7%)
Hypothyroidism 2(3.5%) 6(46.1%)
S.Uric acid (mg/dl) 9.95±2.18 8.29±1.42
Hyper cholesterolemia 23(40.35%) 8(61.53%)
Hyper triglyceridemia 2(3.5%) 0
Both  Hyper 
cholesterolemia,  Hyper 
triglyceridemia
11(19.3%) 5(38.5.%)
S. Creatinine (mg/dl) 1.4±0.88 1.34±0.61
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MUSCULOSKELETAL FEATURES
Polyarticular pattern was seen in 52 patients, (43 males and 9 females). 
Oligoarticular arthritis was seen in 17 patients (13 males and 4 females). The 
first   joint  affected  was   1st MTP   in  31  patients,   knee joints  in 21 
patients  ,small joints of hands  in  9,  ankle in 4,  tarsal in  3,elbows  in 1. One 
patient had bursitis of the foot (lateral malleolus) as the sole musculoskeletal 
manifestation.  First  metatarsophalangeal  joint  involvement  was  seen  in  56 
patients. 20 patients had tophi out of which 18 were men and 2 were women.
JOINT FIRST AFFECTED IN PATIENTS OF GOUT
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TABLE 3: COMPARISON OF OLIGOARTICULAR  AND 
POLYARTICULAR GOUT
Polyarticular Oligoarticular
Number of patients 52(74.28%) 17(24.28%)
Age in Yrs. 47.01±11.81 42.29±7.98
Duration in yrs 4.49±3.99 2.43±2.54
Males 43(82.69%) 13(76.5%)
Females 9(17.3%) 4(23.52%)
Tophi 18(34.6%) 2(11.7%)
Hypertension 30(57.69%) 12(70.58%)
Diabetes Mellitus 5(9.6%) 1(5.8%)
Coronary Artery diseases 7(13.5%) 1(5.8%)
Renal failure 9(17.3%) 0
Hypothyroidism 5(9.6%) 3(17.6%)
S.Uric acid(mg/dl) 10±2.31 8.48±1.05
Hyper cholesterolemia 20(38.5%) 10(58.8%)
Hyper triglyceridemia 2(3.84%) 0
Both  Hyper  cholesterolemia,  Hyper 
triglyceridemia
15(28.84%) 1(5.8%)
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TABLE 4: TOPHACEOUS AND NONTOPHACEOUS   GOUT
TOPHACEOUS 
GOUT
NON TOPHACEOUS 
GOUT
No. of patients 20 50
Serum uric acid
(mg/dl) 10.95±2.02 9.12±1.99
Pattern of arthritis Polyarthritis 18 (90%)
Oligoarthritis 2(10%)
Polyarthritis 34 (68%)
Oligoarthritis 15(30%)
Bursitis 1(2%)
Hypertension 11 (55%) 32 ( 64%)
Diabetes mellitus 2(10%) 4(8%)
Hypothyroidism 1(5%) 7(14%)
Renal failure 4 (20%) 5 (10%)
Dyslipidemia 12 (60 %) 37 (74%)
24 hours 
uricacid 
excretion(mg/day)
692.8±118.88 628.18 ± 179.81
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COMORBIDITIES
1. Hypertension
Hypertension was found in 43 patients out of which 34 had dyslipidemia 
( 27 males and  7 females).Among  the 34 patients  hypercholesterolemia  was 
observed   in  18,(14 males,4 females), hypertriglyceridemia in 2 males and 
both cholesterol and triglyceride were  elevated   in 14  (11 males,3 females).
2. Diabetes mellitus
Diabetes  mellitus  was  present  in   6  patients(8.5%),4  males   and  2 
females ,5 had  hypertension,   dyslipidemia was  present in  all,   coronary 
artery disease in 3, renal  failure in  2.
3. CAD, hypothyrodism, Renal failure
Coronary  artery  disease  was  present  in  8  patients( 7  males  and 1 
female).  Hypothyroidism  was  documented  in  8  patients  (6  females  and  2 
males). Renal failure was present in 9 patients of which 6 are males and 3 are 
females. 
4. Dyslipidemia
Dyslipidemia was present in 49 patients of which hypercholesterolemia 
was noticed in 31 patients (23 males and 8 females) & hypertriglyceridemia 
in  2  males.  Both  cholesterol  and  triglyceride  were  elevated  in  16  patients 
(11males and 5 females).
5. Obesity
Obesity (BMI more than 25 Kg/m2) was observed in 28  (40%) patients 
21 males and 7 females.
TABLE 5: HYPERTENSIVE AND NON  HYPERTENSIVE GOUT
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Hypertensive Non-hypertensive
Number of patients 43 (61.4%) 27(38.57%)
Age in yrs 48.8±11.2 40.96±9.19
Duration in yrs 3.52±3.51 4.61±4.12
Polyarthritis 30(69.76%) 22(81.4%)
Oligoarthritis 12(27.9%) 5(18.6%)
Bursitis 1(2.3%) 0
Tophi 11(25.6%) 9(33.3%)
Diabetes Mellitus 5(11.6%) 1(3.7%)
Coronary Artery diseases 7(16.2%) 1(3.7%)
Renal failure 8(18.6%) 1(3.7%)
Hypothyroidism 6(13.9%) 2(7.4%)
S.Uric acid(mg/dl) 9.87±2.37 9.27±1.73
Hyper cholesterolemia 18(41.8%) 13(48.14%)
Hyper triglyceridemia 2(4.65%) 0
Both  Hyper  cholesterolemia,  Hyper 
triglyceridemia
14(32.6%) 2(7.4%)
LAB INVESTIGATION
The mean ESR was 30 ± 12 mm/hr. The serum uric acid values ranged 
from 7mg/dl to 17.2mg/dl. 15 patients  had  uric acid  levels  between 7 and 8 
mg/dl(6males,9 females),25 patients (22 males ,3 females) had uric acid levels 
between  8 and  9.5mg/dl,11  patients had values  between 9 and 11.5 mg/dl(all 
males), 16  patients with values  between 11 and 15 mg/dl. All the  3 patients 
with  serum  uric acid values  more than 15mg/dl  were  males.13 patients were 
over  excretors of  uric acid (>700 mg/day),2 had  values >1000mg/day.CRP 
was    elevated  in  60  patients(85%).Rheumatoid   factor   was  present   in  2 
patients. Proteinuria was present in 14(20%) patients. 
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RADIOLOGY
All the 20 patients  of  tophaceous  gout  had  radiological evidence of 
tophi  and  erosions of   the  first  MTP  joint.  
CT of the feet was done in 4 patients. It was normal in two patients. The 
third patients had erosion of the 1st MTP joint with tophus . The fourth patient 
had  degenerative  changes  in  the  tibiotalar  joint.  CT  of  hands  done  in  one 
patient showed tophi with destructive arthritis of the proximal interphalangeal 
joints.
Avascular necrosis  was  observed  in 2  patients, left  femoral head in 
one  and right tibial  lateral  condyle  in  the  other.
Renal calculi were present in 5(7.2%) patients. Renal cystic disease was 
seen in 3 patients. 9 patients had renal failure out of which 6 showed significant 
changes in the USG. Fatty liver were present in 31(44.3%) patients.
Intimomedial thickness of carotid arteries was assessed in 50 patients. 
Increased thickness was observed in 5 patients. All of them were hypertensive 
and  dyslipidemic with serum uric  acid levels were more  than 10mg/dl.  4 
patients (80%) had renal failure.
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DISCUSSION
The mean age of onset in our study was 45.81+/-11.05 yrs which was 
comparable to other studies like Porkodi et al (86) 40.02yrs, Kumar et al (78) 
45yrs & Gupta et al(79) 45yrs.Majority of our patients (84.3%) belong to the 
age group between 31 and 60 years whereas 7.3% belong to the Young onset 
group. Danda et al (87) had reported that 17.9% of the patients in his study 
belong to young onset group. There was no statistically significant difference in 
the  serum uric  acid  levels  between the  patients  of  Young onset  group  and 
Classical gout.
The male to female ratio was 57:13in our study whereas in the study of 
Porkodi et al the female population was comparatively lesser (95:6). The mean 
age & duration of the disease were almost the same in both the sexes.  The 
mean serum uric acid levels were higher in the males (9.95+/-2.18 mg/dl) than 
females  (8.29+/-1.42  mg/dl).  Similar  findings  were  noted  in  the  study  of 
Porkodi et al with significantly higher serum uric acid levels in males (10.35) 
as compared to females (8.42 mg/dl). The predominant pattern of arthritis in 
our study in both the sexes was polyarticular (75.43% of males and 69.23% of 
females).In  Porkodi  et  al  study,  the  polyarticular  pattern  was  commoner  in 
females(66.7%)  and  oligoarticular  pattern  was  predominantly  seen  in 
males(80%).The relationship between the sex and pattern of arthritis has not 
been widely discussed in the literature. The serum uric acid levels were higher 
in  polyarticular  group  and  the  difference  is  statistically  significant  (p 
value<0.016).   All the patients with renal failure (9 patients)  had polyarthritis. 
Hyperuricaemia   in  renal  failure is  due to the  reduced uric  acid secretion. 
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Primary hyperuricaemia   in renal disease due to reduced renal uric acid output 
is well documented in the literature.  There could be an indirect relationship 
between  polyarthritis  and  renal  failure,  because  of  higher  serum  uric  acid 
levels.  In  our  study  we  have  found  that  there  is  a  significant  relationship 
between the serum uric levels and higher serum creatinine   levels. Proteinuria 
was  seen  in  20%  of  patients.  Fessel  J  et  al(80)  has  reported  a  20-40% 
prevalence  of  proteinuria  which  is  usually  mild  and  intermittent. 
Nephrolithiasis was present in 5 (7.2%) of patients. Yu T F et al (91) reported a 
10-25% prevalence of the same in patients with primary gout. Hoyosa et al (92) 
found  that  24-36% of  patients  of  polycystic  kidney  disease  develop  gouty 
arthritis. We had a patient of gouty arthritis with polycystic kidney disease and 
renal failure.
Polyarthritis was common in both tophaceous and non tophaceous group 
in our study. The 24 hour uric acid excretion was significantly higher in the 
tophaceous than non tophaceous group (p value<0.016). This does not seem to 
explain the higher prevalence of polyarthritis pattern in the tophaceous group. 
All 20 patients of tophaceous gout had erosions of 1st MTP joint. Erosions in 
chronic gout are common and usually are associated closely with tophaceous 
deposits. These erosions occur secondary to chronic pressure from the adjacent 
tophi. There was one patient with bursitis (1.4%) as the only musculoskeletal 
manifestation. Rheumatoid factor was positive in 2(2.8%) patients. Wallace et 
al  (84)in  his  study  reported  that  10%  of  gouty  patients  were  positive  for 
rheumatoid factor. Kozin et  al (85) found  that  one  third  of  patients  of 
tophaceous  gout  had  rheumatoid factor  positivity.
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MUSCULOSKELETAL INVOLVEMENT IN GOUT
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The most common co morbidities in our study was hypertension .The 
other  common  co  morbidities  were  obesity,  coronary  heart  disease 
hypothyroidism  &  renal  failure.
The prevalence of hypertension was almost equal in both the sexes. Poly 
arthritis pattern was the predominant pattern in majority of the hypertensive 
patients  and  there  was  no  significant  difference  in  serum  uric  acid  levels 
between the hypertensive and non hypertensive patients in our study. Porkodi 
et al and Johnson RJ has stated a positive relationship between hyperuricemia 
and hypertension.
Majority  of  the  patients  with  dyslipidemia  were  having  high  serum 
cholesterol levels and only 2 had higher triglyceride levels and some of them 
had  both  the  cholesterol  and  triglyceride  levels  elevated.  There  was  no 
correlation between serum cholesterol and serum uric acid levels in our study. 
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Scott J et al  (81) in his  study  also concluded the  same in  his study. Many 
studies  have  concluded  the  direct  relationship  between  hyperuricaemia  and 
dyslipidemia, obesity and to their potential adverse effects. 
Coronary heart disease was an important co morbidity seen in 11.4% 
patients  in  our  study.  Alderman  et  al  reported  that  hyperuricemia  is  an 
important  risk  factor  for  ischemic  heart  disease.  Nagahama  et  al  (25)  has 
reported  the  clustering  of  hyperuricemia  with  cardiovascular  factors.    The 
National health and Nutrition examination survey (NHANES) is a population 
based cross sectional study conducted to determine the risk of elevated serum 
uric  acid  levels  in  cardiovascular  mortality.  The  study  concluded  that  high 
serum uric acid levels has a significant risk of cardiovascular mortality. In our 
study,  we  found  that  serum uric  acid  levels  to  be  relatively  higher  in  the 
patients with coronary heart disease. Intimomedial thickness was also found to 
be increased in 3 of these patients. Five out of fifty patients in our study were 
found  to  have  increased  Intimomedial  thickness.  All  the  five  patients  were 
hypertensive  and  hyperlipidemic  with  serum  uric  acid  levels  more  than 
10mg/dl.
A significant co relation between hypothyroidism and defective purine 
metabolism and hyperuricemia has been noted in the past literature. The cause 
for hyperuricemia in hypothyroidism is due to reduced renal plasma flow and 
impaired  glomerular  filtration.  All  our  patients  with  hypothyroidism in  our 
study have relatively higher mean serum uric acid levels. Erickson AR(93) has 
reported increased prevalence of hypothyroidism in patients with gouty arthritis 
as  compared  to  the  control  group.  In  the  study  of  Erickson  et  al, 
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hypothyroidism was prevalent in 15% of patients of gout in 25% of females 
and 12% of males (a 2.5 times greater prevalence in women and 6 times greater 
prevalence in men than normal population).
Diabetes mellitus was present in 8.57 %( 6) of patients in our study. 
Umber et  al  (89)  reported a 5.4% prevalence of  diabetes  in gouty patients. 
Whitehouse  and  Cleary(90)  found  diabetes  in  18%  patients  of  gout  as 
compared to 19% in controls.  Bakowitz (88) reported a correlation between 
hyperuricemia  and  hypertriglyceridemia  and  an  association  of 
hypertriglyceridemia with decreased glucose tolerance.  In our  study 5(83%) 
patients  of  gouty  diabetics  had  hypercholesterolemia  and  50%  had 
hypertriglyceridemia.
AVN  has  been  reported in hyperuricemia  of  renal failure  of  post 
transplant  patients. In our  study  one  had AVN  of  the  head  of  femur  and 
the other had  in  the  lateral  tibial  condyle. Mc Collum et al ( 83 )  in his 
study of  AVN   and  associated  diseases found an  association  of  gout  with 
AVN.
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CONCLUSIONS
 Majority of the patients (79%) of gout in our study belonged to the age 
group  of 31-60 years .
 Predominant pattern of arthritis was polyarticular.
 Five patients in our study belong to the Young onset group.
 Dyslipidemia and Hypertension were the common co morbidities in the 
male population.
 Hypertension, Dyslipidemia and Hypothyroidism were the common co 
morbidities in our female patients.
 A strong association between polyarticular gout and renal failure was 
noticed.
 Serum uric acid levels were higher in males than females.
 There was a significant correlation between uric acid levels and serum 
creatinine.
 The 24 hours uric acid excretion was higher in tophaceous gout than the 
non tophaceous gout.
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ABBREVIATIONS
ACTH adrenocorticotrophic hormone
AVN avascular necrosis
BMI body  mass index
CAD coronary  artery  disease
CI confidence interval
CIA crystal induced arthritis
CRP C reactive protein
DM diabetes  mellitus
HTN hypertension
LTB leukotriene B
ICAM inter cellular  adhesion molecule
IMT intimimedial  thickness
IL interleukin
HTN hypertension
MSU monosodium urate
MMP matrix metalloproteinase
NO Nitric oxide
MTP metatarsophalangeal
RF Rheumatoid  factor
RR relative risk
TGF Transforming  growth  factor
TLR Toll like receptor
TNF Tumour  necrosis  factor
USG Ultrasonogram
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CRITERIA FOR THE CLASSIFICATION FOR ACUTE 
GOUTY ARTHRITIS
The  presence  of  characteristics  urate  crystals  in  the  joint  fluid,  or  a 
tophus proved to contain  urate crystals by chemical means or polarized light 
microscopy, or the presence of 6 of the following 12 clinical, laboratory, and 
radiographic phenomena:
I. More than one attack of acute arthritis
II. Maximal inflammation developed within 1 day
III. Attack of monarticular arthritis
IV. Joint redness observed
V. First metatarsophalangeal joint painful or swollen
VI. Unilateral attack involving first metatarsophalangeal joint.
VII. Unilateral attack involving tarsal joint
VIII. Suspected tophus
IX. Hyperuricemia
X. Asymmetric swelling within a joint (radiograph)
XI. Subcortical cysts without erosions (radiograph)
XII. Negative  culture  of  joint  fluid for  microorganisms during  attack of 
joint inflammation.
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PROFORMA
NAME
Age                                                          Sex
Occupation                                             Address
Duration of disease
Present history
Joints  involved  first
Joints  involved later
Number  of  previous  episodes 
Pain and swelling  of  1st MTP joint
Pain swelling  of  any  other  soft  tissues
Past  history
CAD
Hypothyroidism
          Hypertension
Drug history
Low dose aspirin
          Diuretics others
Personal  history
Smoking
Alcohol
Tobacco  chewing
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Family history
Examination
Height            Weight   Skin Tophi                   Goitre
Cardiovascular system
Respiratory system
Abdomen
CNS
Musculoskeletal System
Joint (R)W (R)S (R)T (R)L (L)W (L)S (L)T (L)L
PIP
MCP
WRIST
ELBOW
SHOULDER
KNEE
ANKLE
MTP
IP
HIP
BURSITIS
OTHERS
INVESTIGATIONS
Hemoglobin
TC
DC
ESR
PLATELET
Urine routine
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Urea
Creatinine
SGOT
SGPT
Cholesterol
Triglyceride
HDL
LDL
S.Uricacid
24 hour uric acid
T3 ,T4,TSH
RF
CRP
XRAY
USG ABDOMEN
IMT CAROTIDS ECHO
CT
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